Navigation Links
Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference

CALGARY, June 01, 2007 /PRNewswire-FirstCall/ - Research collaborators with Oncolytics Biotech Inc. ("Oncolytics") are scheduled to deliver a poster presentation covering REOLYSIN(R) clinical trial data at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 1-5, 2007 in Chicago. The data cover final results of Oncolytics' U.K. Phase I systemic administration trial.

The poster, entitled "Final Results of a Phase I Study of Wild-Type Oncolytic Reovirus Administered Intravenously to Patients with Advanced Cancer" is scheduled to be presented by Dr. James Spicer of The Royal Marsden Hospital and The Institute of Cancer Research, U.K. on Sunday, June 3, 2007.

The poster will be available on the Oncolytics website on Monday, June 4, 2007.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials to be presented at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking sta tements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.

CONTACT: Oncolytics Biotech Inc., Cathy Ward, 210, 1167 Kensington Cr NW,Calgary, Alberta, T2N 1X7, Tel: (403) 670-7377, Fax: (403) 283-0858,; The Equicom Group, Nick Hurst, 325, 300 5th Ave.SW, Calgary, Alberta, T2P 3C4, Tel: (403) 538-4845, Fax: (403) 237-6916,; The Investor Relations Group, Erika Moran, 11Stone St, 3rd Floor, New York, NY 10004, Tel: (212) 825-3210, Fax: (212)825-3229, cathy.ward@oncolytics.ca nhurst@equicomgroup.com emoran@investorrelationsgroup.com

Ticker Symbol: (Toronto:ONC.),(NASDAQ-NMS:ONCY)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S. Phase I REOLYSIN Trial
2. Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines
3. Oncolytics Biotech Inc. Collaborators to Present Reovirus/Gemcitabine Combination Research at AACR Annual Meeting
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
8. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
9. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
10. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
11. Prana Biotechnology Presents New Key Findings on PBT2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... , Aug. 2, 2017 CaryRx, a next-generation full-service ... delivery service for patients in the Washington D.C. ... retail pharmacy by providing delivery of medications through the convenience ... future delivery or delivered within one hour to any location ... excited to bring this invaluable service to Washington ...
(Date:7/31/2017)... , July 31, 2017 7D Surgical, developer ... Medical has purchased the 7D Surgical System to support its ... Washington D.C. and Virginia.  7D Surgical has ... for many of the premier medical facilities within those markets. ... ...
(Date:7/27/2017)... Services, Inc. (NYSE: WST ) today announced ... financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record high, ... constant currency (organic) grew by 3.9%. ... in the prior-year quarter. Second-quarter 2017 adjusted diluted EPS ...
Breaking Medicine Technology:
(Date:8/18/2017)... New York (PRWEB) , ... August 18, 2017 ... ... leading manufacturers and marketers of high-quality anti-aging skincare solutions, recently announced ... Serum. These new products are an affordable, yet effective alternative to expensive plastic ...
(Date:8/18/2017)... ... 18, 2017 , ... “Prompted By Love”: a love story thrown into doubt ... Nettles. Author Mary P. Nettles has devoted her life to ministry since the ... lifelong desire to write was, however, not fulfilled until 2014 when "The Color of ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Case ... Veterans Affairs Medical Center. “Case #10-5411 Veterans Administration” is the creation of ... abuse. In June 1990, Carol Mulhem started work at the Coatesville VAMC ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... organizations and considered extremely effective, very effective, or effective by 85% of respondents, ... , NEJM Catalyst Insights Reports are based on surveys of the NEJM Catalyst ...
(Date:8/17/2017)... ... , ... When Amy Cowperthwait left the emergency room after 28 ... dream to make nursing education more relevant and prepare aspiring nurses to address both ... healthcare provider education. , “The human element was missing. Students were learning ...
Breaking Medicine News(10 mins):